Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study.

Joensuu JT, Aaltonen KJ, Aronen P, Sokka T, Puolakka K, Tuompo R, Korpela M, Vasala M, Ilva K, Nordström D, Blom M.

Rheumatology (Oxford). 2016 Oct;55(10):1803-11. doi: 10.1093/rheumatology/kew264. Epub 2016 Jun 27.

PMID:
27354689
2.

Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial.

Kuusalo L, Puolakka K, Kautiainen H, Blåfield H, Eklund KK, Ilva K, Kaipiainen-Seppänen O, Karjalainen A, Korpela M, Valleala H, Leirisalo-Repo M, Rantalaiho V; Neo-RACo Study Group.

Scand J Rheumatol. 2015;44(6):449-55. doi: 10.3109/03009742.2015.1043142. Epub 2015 Aug 31.

PMID:
26324784
3.

Physicians' adherence to tight control treatment strategy and combination DMARD therapy are additively important for reaching remission and maintaining working ability in early rheumatoid arthritis: a subanalysis of the FIN-RACo trial.

Rantalaiho V, Kautiainen H, Korpela M, Puolakka K, Blåfield H, Ilva K, Hannonen P, Leirisalo-Repo M, Möttönen T; FIN-RACo Study Group.

Ann Rheum Dis. 2014 Apr;73(4):788-90. doi: 10.1136/annrheumdis-2013-204271. Epub 2013 Dec 2. No abstract available.

PMID:
24297374
4.

Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).

Leirisalo-Repo M, Kautiainen H, Laasonen L, Korpela M, Kauppi MJ, Kaipiainen-Seppänen O, Luosujärvi R, Luukkainen R, Karjalainen A, Blåfield H, Uutela T, Ilva K, Julkunen HA, Paimela L, Puolakka K, Moilanen E, Hannonen PJ, Möttönen T; NEO-RACo Study Group.

Ann Rheum Dis. 2013 Jun;72(6):851-7. doi: 10.1136/annrheumdis-2012-201365. Epub 2012 Jun 30.

PMID:
22753402
5.

Rheumatoid atlantoaxial subluxation can be prevented by intensive use of traditional disease modifying antirheumatic drugs.

Kauppi MJ, Neva MH, Laiho K, Kautiainen H, Luukkainen R, Karjalainen A, Hannonen PJ, Leirisalo-Repo M, Korpela M, Ilva K, Möttönen T; FIN-RACo Trial Group.

J Rheumatol. 2009 Feb;36(2):273-8. doi: 10.3899/jrheum.080429.

PMID:
19132793
6.

Cost of Finnish statutory inpatient rehabilitation and its impact on functional and work capacity of patients with early rheumatoid arthritis: experience from the FIN-RACo trial.

Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Pohjolainen T, Korpela M, Vuori K, Ilva K, Yli-Kerttula U, Järvinen P, Leirisalo-Repo M.

Scand J Rheumatol. 2007 Jul-Aug;36(4):270-7.

PMID:
17763204
7.

Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience.

Nordström DC, Konttinen L, Korpela M, Tiippana-Kinnunen T, Eklund K, Forsberg S, Ilva K, Kaipiainen-Seppänen O, Malmi T, Ylä-Kerttula T, Honkanen V.

Rheumatol Int. 2006 Jun;26(8):741-8. Epub 2005 Oct 5.

PMID:
16205925
8.

Predictors of productivity loss in early rheumatoid arthritis: a 5 year follow up study.

Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Hakala M, Korpela M, Ilva K, Yli-Kerttula U, Piirainen H, Leirisalo-Repo M; FIN-RACo Trial Troup.

Ann Rheum Dis. 2005 Jan;64(1):130-3.

9.

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.

Möttönen T, Hannonen P, Leirisalo-Repo M, Nissilä M, Kautiainen H, Korpela M, Laasonen L, Julkunen H, Luukkainen R, Vuori K, Paimela L, Blåfield H, Hakala M, Ilva K, Yli-Kerttula U, Puolakka K, Järvinen P, Hakola M, Piirainen H, Ahonen J, Pälvimäki I, Forsberg S, Koota K, Friman C.

Lancet. 1999 May 8;353(9164):1568-73.

PMID:
10334255

Supplemental Content

Support Center